INVALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒═══════════════════════════════════════════════════╤═══════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                 │ CHIA Criteria                                     │   Score │
╞═══════════════════════════════════════════════════╪═══════════════════════════════════════════════════╪═════════╡
│ Patients with angina or silent ischemia and       │ Patients with angina or silent ischemia and       │     100 │
│ documented ischemia                               │ documented ischemia                               │         │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Patients who are eligible for intracoronary       │ Patients who are eligible for intracoronary       │     100 │
│ stenting                                          │ stenting                                          │         │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ De novo lesion CTO                                │ De novo lesion CTO                                │     100 │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Reference vessel size 2.5 mm by visual estimation │ Reference vessel size 2.5 mm by visual estimation │     100 │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ At least one CTO lesions located in proximal or   │ At least one CTO lesions located in proximal or   │     100 │
│ mid epicardial coronary artery. (If the patient   │ mid epicardial coronary artery. (If the patient   │         │
│ has two CTO lesions, one CTO lesion should be     │ has two CTO lesions, one CTO lesion should be     │         │
│ located in proximal or mid epicardial coronary    │ located in proximal or mid epicardial coronary    │         │
│ artery)                                           │ artery)                                           │         │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Angiographically defined total occlusion over 3   │ Angiographically defined total occlusion over 3   │     100 │
│ months                                            │ months                                            │         │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ If no definite symptom with total occlusion, two  │ If no definite symptom with total occlusion, two  │     100 │
│ experienced operators decide CTO in consideration │ experienced operators decide CTO in consideration │         │
│ of angiographical morphology (degree of           │ of angiographical morphology (degree of           │         │
│ calcification, bridging collaterals, non-tapered  │ calcification, bridging collaterals, non-tapered  │         │
│ stump, angiographic filling from collaterals)     │ stump, angiographic filling from collaterals)     │         │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Age \> 18 years                                   │ Age > 18 years                                    │      97 │
╘═══════════════════════════════════════════════════╧═══════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒════════════════════════════════════════════════════╤═══════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                     │   Score │
╞════════════════════════════════════════════════════╪═══════════════════════════════════════════════════╪═════════╡
│ Clinical                                           │ De novo lesion CTO                                │      23 │
├────────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Pregnant state                                     │ Patients who are eligible for intracoronary       │      33 │
│                                                    │ stenting                                          │         │
├────────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Hematological disease                              │ Angiographically defined total occlusion over 3   │      35 │
│                                                    │ months                                            │         │
├────────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Angiographic                                       │ Angiographically defined total occlusion over 3   │      36 │
│                                                    │ months                                            │         │
├────────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Hepatic dysfunction, liver enzyme (ALT and AST)    │ Patients with angina or silent ischemia and       │      37 │
│ elevation 3 times normal                           │ documented ischemia                               │         │
├────────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Renal dysfunction, creatinine more than 2.0        │ Angiographically defined total occlusion over 3   │      39 │
│                                                    │ months                                            │         │
├────────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Non-cardiac co-morbid conditions are present with  │ At least one CTO lesions located in proximal or   │      40 │
│ limited life expectancy or that may result in      │ mid epicardial coronary artery. (If the patient   │         │
│ protocol non-compliance (per site investigator's   │ has two CTO lesions, one CTO lesion should be     │         │
│ medical judgment)                                  │ located in proximal or mid epicardial coronary    │         │
│                                                    │ artery)                                           │         │
├────────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ History of bleeding diathesis or coagulopathy      │ Patients who are eligible for intracoronary       │      41 │
│                                                    │ stenting                                          │         │
├────────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Left ventricular ejection fraction                 │ Reference vessel size 2.5 mm by visual estimation │      41 │
├────────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Patients who are actively participating in another │ Patients with angina or silent ischemia and       │      42 │
│ drug or device investigational study, which have   │ documented ischemia                               │         │
│ not completed the primary endpoint follow-up       │                                                   │         │
│ period                                             │                                                   │         │
├────────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ CTO definition: TIMI flow 0 and estimated duration │ If no definite symptom with total occlusion, two  │      43 │
│ over 3 months The duration of the occlusion was    │ experienced operators decide CTO in consideration │         │
│ determined by the interval from the last episode   │ of angiographical morphology (degree of           │         │
│ of acute coronary syndrome, or In patients without │ calcification, bridging collaterals, non-tapered  │         │
│ a history of acute coronary syndrome, from the     │ stump, angiographic filling from collaterals)     │         │
│ first episode of effort angina consistent with the │                                                   │         │
│ location of the occlusion                          │                                                   │         │
├────────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Known hypersensitivity or contra-indication to     │ Patients who are eligible for intracoronary       │      43 │
│ contrast agent and heparin                         │ stenting                                          │         │
├────────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Contraindication to aspirin, clopidogrel or other  │ Patients who are eligible for intracoronary       │      44 │
│ commercial antiplatelet agent                      │ stenting                                          │         │
├────────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Must have minimum age of 18 Years                  │ Age > 18 years                                    │      47 │
├────────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Characteristics of lesion 1) Left main disease 2)  │ At least one CTO lesions located in proximal or   │      47 │
│ In-stent restenosis 3) Graft vessels 4) Distal     │ mid epicardial coronary artery. (If the patient   │         │
│ epicardial coronary artery CTO lesions             │ has two CTO lesions, one CTO lesion should be     │         │
│                                                    │ located in proximal or mid epicardial coronary    │         │
│                                                    │ artery)                                           │         │
├────────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ ST-elevation acute myocardial infarction requiring │ Patients who are eligible for intracoronary       │      52 │
│ primary stenting                                   │ stenting                                          │         │
├────────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Three vessel CTO                                   │ De novo lesion CTO                                │      53 │
╘════════════════════════════════════════════════════╧═══════════════════════════════════════════════════╧═════════╛

Only CHIA has the following criteria:
╒═════════════════════╤═════════════════╤═════════╕
│ Personal Criteria   │ CHIA Criteria   │   Score │
╞═════════════════════╪═════════════════╪═════════╡
│ Angiographic        │ NA              │      14 │
╘═════════════════════╧═════════════════╧═════════╛

Levenshtein Ratio of Entire trial at once: 51
Average Levenshtein Ratio of individual lines: 57.96153846153846
OverAll Ratio: 54.480769230769226
